{"filings":[{"id":1811596,"accession_number":"0001022079-26-000067","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-07-23T10:46:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.","Reported diluted EPS $2.84 (+15% YoY); adjusted diluted EPS $3.12 (+19.1% YoY).","FY2026 revenue guidance raised to $11.95B-$12.05B; adjusted EPS guidance raised to $11.05-$11.25.","Q2 cash from operations $597M, up 9.7% YoY.","Advanced Diagnostics growth (Alzheimer's, cardiometabolic); NY approval for Haystack MRD test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583516,"accession_number":"0001022079-26-000052","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-05-21T20:48:35+00:00","items":["5.07"],"status":"ready","headline":"Quest Diagnostics elects all 11 director nominees; stockholder proposal on independent chairman rejected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Timothy M. Ring received 81.9M for, 12.0M against (lowest support).","Advisory say-on-pay resolution approved: 86.9M for, 7.2M against.","Ratification of PwC as auditor approved: 97.3M for, 5.8M against.","Stockholder proposal for independent board chairman rejected: 24.0M for, 69.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90653,"accession_number":"0001104659-26-057938","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Quest Diagnostics issues $500M of 5.000% senior notes due 2036","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M aggregate principal, 5.000% coupon, maturity June 30, 2036.","Interest payable semi-annually on June 30 and Dec 30, beginning Dec 30, 2026.","Senior unsecured, ranks equally with existing senior debt; no sinking fund.","Upon a change of control triggering event, repurchase at 101% plus accrued interest.","Issued under existing indenture as supplemented by twenty-fourth supplemental indenture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90652,"accession_number":"0001104659-26-054141","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Quest Diagnostics prices $500M of 5.000% senior notes due 2036","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M aggregate principal of 5.000% senior notes due 2036 priced under shelf registration.","Net proceeds for general corporate purposes, may repay $500M 3.45% notes maturing June 1, 2026.","Closing expected May 6, 2026, subject to customary closing conditions.","Underwriting agreement with Goldman Sachs, J.P. Morgan, and Mizuho Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90651,"accession_number":"0001022079-26-000040","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q1 revenue $2.90B (+9.2%), raises FY2026 EPS and revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported diluted EPS $2.24 (+15.5%); adjusted diluted EPS $2.50 (+13.1%).","Requisition volume up 10.9% organic; revenue per requisition down 1.3%.","FY2026 adjusted EPS guidance raised to $10.63-$10.83 from $10.50-$10.70; revenue now $11.78-$11.90B.","Operating income margin improved to 15.4% adjusted; cash from ops $278M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":2895000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100348,"accession_number":"0000947871-26-000244","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics elects former Walgreens CEO Timothy Wentworth to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, as director effective March 9, 2026.","Appointed to Compensation and Leadership Development and Quality and Compliance Committees.","Received prorated restricted share unit grant valued at approximately $43,000 upon joining board.","Board now consists of 11 members including Wentworth.","Wentworth also previously CEO of Evernorth Health Services and Express Scripts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100347,"accession_number":"0001022079-26-000005","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 rev $2.81B (+7.1%), adj EPS $2.42 (+8.5%); raises dividend 7.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $11.04B (+11.8%), reported EPS $8.75 (+13.8%), adjusted EPS $9.85 (+10.3%).","Q4 organic requisition volume +7.9%; operating cash flow $465M; FY cash from ops $1.89B.","FY2026 guidance: revenue $11.70B-$11.82B, adjusted EPS $10.50-$10.70.","Quarterly dividend raised 7.5% to $0.86/share, payable Apr 20, 2026 to holders of record Apr 6, 2026.","Board authorized additional $1B share repurchase; $0.4B remained from prior program."],"consensus_eps_estimate":null,"consensus_eps_actual":8.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":11035000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100346,"accession_number":"0000947871-26-000025","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics presents at J.P. Morgan Healthcare Conference; no new financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Discussed strategy, performance, market developments and trends; no specific financial details.","No new quantitative updates, guidance, or targets in the filed presentation materials.","Presentation includes standard forward-looking statements and risk factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116681,"accession_number":"0001022079-25-000219","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.","Revenue up 13.1% to $2.82B with 6.8% organic growth; diagnostic info services revenue $2.76B.","FY2025 adjusted EPS guidance raised to $9.76–$9.84 from $9.63–$9.83; revenue guidance raised to $10.96B–$11.00B.","Year-to-date cash from operations $1.42B, up 63.1%; Co-Lab Solutions annual revenue run-rate ~$1B expected next year.","Announced lab services JV with Corewell Health; acquired dialysis testing assets from Fresenius Medical Care."],"consensus_eps_estimate":null,"consensus_eps_actual":6.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":8229000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133124,"accession_number":"0001022079-25-000172","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q2 revenues $2.76B (+15.2%), beats; raises FY2025 adjusted EPS guidance to $9.63-$9.83","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $2.76B, up 15.2% YoY; organic revenue growth 5.2%.","Reported diluted EPS $2.47 (+21.7%); adjusted diluted EPS $2.62 (+11.5%).","Cash from operations $544M in Q2 (+51.5%); YTD $858M (+67.1%).","Raises full-year 2025 net revenue guidance to $10.80B-$10.92B (from $10.70B-$10.85B).","FY2025 adjusted diluted EPS guidance raised to $9.63-$9.83 from $9.55-$9.80."],"consensus_eps_estimate":null,"consensus_eps_actual":4.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":5413000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149728,"accession_number":"0001022079-25-000154","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quest Diagnostics 2025 meeting: all director nominees elected, exec comp approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; highest vote for Robert B. Carter (94.2M for), lowest for Timothy M. Ring (87.2M for).","Advisory vote on executive compensation passed: 85.9M for, 8.6M against.","Ratification of PwC as auditor for 2025 approved: 95.6M for, 6.9M against.","Stockholder proposal on special meetings defeated: 84.4M against, 9.5M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149727,"accession_number":"0001022079-25-000116","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q1 revenue up 12.1% to $2.65B, raises FY reported EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenues $2.65B (+12.1% YoY); reported diluted EPS $1.94 (+12.8%), adjusted diluted EPS $2.21 (+8.3%).","Organic revenue growth nearly 2.5%; requisition volume up 12.4%, organic volume down 0.9%.","Operating income $346M (13.0% margin); adjusted operating income $406M (15.3% margin).","Full year 2025 reported diluted EPS guidance raised to $8.62-$8.87 from prior $8.34-$8.59; adjusted EPS reaffirmed $9.55-$9.80.","Cash from operations guidance raised to ~$1.5B from ~$1.45B; capex unchanged at ~$500M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":2652000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168759,"accession_number":"0000947871-25-000321","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quest Diagnostics holds Investor Day; strategic presentations on innovation, operations, and financial outlook","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Jim Davis presented on driving sustainable growth and delivering long-term value.","Karthik Kuppusamy discussed diagnostic innovation as a growth driver.","Cathy Doherty and Alex Louis presented on improving quality, experiences, and productivity.","CFO Sam Samad outlined long-term financial outlook; specific numbers not available from exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168758,"accession_number":"0000947871-25-000317","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quest Diagnostics provides long-term outlook: 4-5% revenue CAGR; reaffirms FY2025 guidance but notes Q1 weather headwind","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Long-term outlook: revenue CAGR 4-5%, adjusted EPS CAGR 7-9% beyond 2025.","Reaffirms FY2025 guidance: revenue $10.70B-$10.85B, adjusted EPS $9.55-$9.80.","Q1 2025 weather headwind of ~$25M revenue and ~$0.10 EPS expected.","Strategic initiatives include Invigorate productivity (3% annual savings) and Project Nova IT modernization.","Double-digit growth targeted in advanced diagnostics: oncology, cardiometabolic, brain health, others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168757,"accession_number":"0001022079-25-000008","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 revenue $2.62B (+14.5%), adjusted EPS $2.23 (+3.7%); raises dividend 6.7% to $0.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.62B (+14.5% YoY); reported diluted EPS $1.95 (+14.7%); adjusted diluted EPS $2.23 (+3.7%).","Full year 2024 revenue $9.87B (+6.7%); reported EPS $7.69 (+2.7%); adjusted EPS $8.93 (+2.5%).","FY2025 guidance: revenue $10.70-10.85B; reported EPS $8.34-8.59; adjusted EPS $9.55-9.80; cash ops ~$1.45B.","Quarterly dividend raised 6.7% to $0.80 ($3.20 annual), payable Apr 21, 2025 to holders of record Apr 7, 2025.","Completed 8 acquisitions in 2024 (including LifeLabs); extended health plan access to >90% of in-network lives."],"consensus_eps_estimate":null,"consensus_eps_actual":7.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":9872000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185885,"accession_number":"0001022079-24-000187","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q3 revenue +8.5% to $2.49B, raises FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $2.49B (+8.5% YoY); reported EPS $1.99 (+1.5%); adjusted EPS $2.30 (+3.6%).","Organic revenue growth 4.2%; revenue per requisition +3.3%, volume +5.5%.","FY2024 revenue guidance raised to $9.80-9.85B (from $9.50-9.58B); adjusted EPS guidance unchanged at $8.85-8.95.","Hurricane Milton expected to reduce Q4 revenue by ~$15M and EPS by ~$0.08.","CEO cites customer wins and acquisitions including LifeLabs; 8 acquisitions targeted by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":5.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":7251000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202452,"accession_number":"0001022079-24-000173","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Quest Diagnostics closes LifeLabs acquisition; terms not disclosed","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Acquisition of LifeLabs Inc., a Canadian lab diagnostics and digital health company, closed on August 26, 2024.","Deal was originally announced on July 2, 2024 via equity purchase agreement with Borealis Infrastructure and others.","No purchase price, financing details, or expected synergies provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202451,"accession_number":"0001104659-24-090867","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.","Net proceeds to fund LifeLabs purchase price and related costs, plus general corporate purposes.","2027 and 2029 notes subject to special mandatory redemption at 101% if LifeLabs deal not completed.","2034 notes will remain outstanding even if LifeLabs acquisition is not consummated.","By-laws amended to provide officer exculpation as permitted by Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202450,"accession_number":"0001022079-24-000153","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics beats Q2 estimates, raises full-year guidance; announces four acquisitions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenues $2.397B (+2.5% YoY); reported EPS $2.03 (-1% YoY), adjusted EPS $2.35 (+2.2% YoY)","Full-year 2024 revenue guidance raised to $9.50-9.58B; adjusted EPS raised to $8.80-9.00","Announces four acquisitions: LifeLabs (pending), Allina Health, OhioHealth outreach labs, PathAI Diagnostics (completed)","Base business revenue growth ~4%; driven by new customers, advanced diagnostics, healthcare utilization","Cash from ops guided ~$1.3B; capex ~$420M; both unchanged from prior guidance"],"consensus_eps_estimate":null,"consensus_eps_actual":3.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":4763000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202449,"accession_number":"0000947871-24-000587","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35B (~US$985M)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash purchase price of ~C$1.35B (US$985M) including net debt, funded with cash and debt.","LifeLabs generates ~C$970M (US$710M) annual revenue; deal slightly dilutive to GAAP EPS but accretive to adjusted EPS in first 12 months.","LifeLabs will retain its brand, Canadian HQ, and management; Quest to provide expertise and resources.","Closing expected by end of 2024, subject to Canadian regulatory approvals and key customer consents.","LifeLabs has >6,500 employees and is a leading Canadian community lab; existing reference relationship with Quest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218585,"accession_number":"0001022079-24-000138","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics elects FedEx CIO Robert B. Carter to board; board now 10 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert B. Carter, EVP and CIO of FedEx, elected to Quest's Board effective May 16, 2024.","Carter also serves as Co-President and Co-CEO of FedEx Services; will step down from FedEx in June 2024.","Carter has technology and cybersecurity expertise; serves on New York Life board and previously First Horizon and Saks.","Board determined Carter is independent under NYSE standards; committee assignments pending.","Carter will receive standard non-employee director compensation as per Quest's practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218584,"accession_number":"0001022079-24-000133","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Quest Diagnostics shareholders approve officer exculpation, elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Officer exculpation amendment approved with 80.2M for, 13.0M against; effective May 20, 2024.","All nine director nominees elected; vote totals ranged from 85.3M (Gary Pfeiffer) to 92.8M (Tracey Doi).","Advisory say-on-pay approved with 82.5M for, 10.6M against, 0.4M abstain.","Ratification of PricewaterhouseCoopers as auditor for 2024 approved with 96.5M for, 5.6M against.","Shareholder proposal on climate risk/science-based targets not approved; 39.1M for, 53.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218583,"accession_number":"0001022079-24-000096","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q1 revenue $2.37B (+1.5% YoY); raises full-year adjusted EPS to $8.72-$8.97","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.366B, up 1.5% YoY; base business revenue grew nearly 6%.","Reported diluted EPS $1.72 (down 3.4%); adjusted diluted EPS $2.04 (flat YoY).","Full-year 2024 guidance raised: revenue $9.40B-$9.48B, adjusted EPS $8.72-$8.97.","Invigorate initiative driving productivity; growth in brain, women's, and cardiometabolic health.","Cash from operations $154M (+64.8%); capex $104M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":2366000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238477,"accession_number":"0001022079-24-000009","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 2023 adjusted EPS $2.15, +8.6%; base business revenue +4.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported net revenue $2.29B (-1.9% YoY); base business revenue $2.25B (+4.7%).","Q4 reported diluted EPS $1.70 (+95.4%); adjusted diluted EPS $2.15 (+8.6%).","Full year 2023 base business revenue grew 7.1% to $9.03B; COVID testing fell 84.7% to $223M.","Quarterly dividend raised 5.6% to $0.75; payable April 22, 2024 to record date April 8.","FY2024 guidance: revenue $9.35-$9.45B; reported EPS $7.69-$7.99; adjusted EPS $8.60-$8.90."],"consensus_eps_estimate":null,"consensus_eps_actual":7.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":9252000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255987,"accession_number":"0001022079-23-000172","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics issues $750M of 6.400% senior notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$750M aggregate principal; 6.400% coupon; mature Nov 30, 2033; interest paid semi-annually May 30 & Nov 30.","Proceeds for general corporate purposes, may redeem/repay $300M of 4.25% senior notes due 2024 and credit facility borrowings.","Offering priced Oct 30, 2023; closed Nov 1, 2023; joint book-runners Goldman Sachs, Mizuho, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255986,"accession_number":"0001022079-23-000154","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).","Base business revenue $2.27B (+4.6% YoY); COVID-19 testing revenue $26M (down 92% YoY).","FY2023 guidance: revenue $9.19B-$9.24B, adjusted EPS $8.65-$8.75, raised low end from prior.","Successfully negotiated all strategic health plan renewals for 2023; cites strong physician/hospital channels.","Operating cash flow $207M in Q3 vs $502M year ago; capex $105M."],"consensus_eps_estimate":null,"consensus_eps_actual":5.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":6964000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273378,"accession_number":"0001022079-23-000147","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Gail R. Wilensky to retire from Quest Diagnostics Board in May 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gail R. Wilensky notified Quest on Sept 28, 2023 that she will not stand for re-election at the 2024 Annual Meeting.","Her retirement from the Board will be effective as of the date of the 2024 Annual Stockholders Meeting in May 2024.","No replacement for the departing director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273377,"accession_number":"0001022079-23-000131","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q2 revenue $2.34B down 4.7% YoY; base business up 9.5%; raises FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 reported EPS $2.05 (+4.6% YoY); adjusted EPS $2.30 (-2.5% YoY).","Base business revenue $2.30B (+9.5% YoY); COVID testing revenue $41M (-88.3%).","FY 2023 revenue guidance raised to $9.12B-$9.22B (from $8.93B-$9.08B).","Adjusted EPS guidance $8.50-$8.90; cash from operations at least $1.3B.","CEO cites strong base business demand but persistent labor turnover pressures."],"consensus_eps_estimate":null,"consensus_eps_actual":3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":4669000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290338,"accession_number":"0001022079-23-000104","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quest Diagnostics shareholders approve all proposals, reject GHG emissions report","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; James E. Davis received ~86M for, 6M against.","Advisory say-on-pay approved with 83.3M for vs 9.1M against; frequency set at 1 year.","Ratification of PwC as auditor passed with 95.9M for, 5.97M against.","Amended Employee Long-Term Incentive Plan approved: 82.0M for, 10.4M against.","Stockholder proposal for GHG emissions report rejected: 44.2M for, 47.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290337,"accession_number":"0001022079-23-000091","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q1 revenue falls 10.7% to $2.33B; acquires Haystack Oncology for $300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 net revenue $2.33B, down 10.7% YoY; base business revenue up 10% to $2.21B.","Reported diluted EPS $1.78 (down 39%); adjusted diluted EPS $2.04 (down 36.6%).","Full-year 2023 guidance: revenue $8.93B-$9.08B, adjusted EPS $8.45-$8.95.","Acquires Haystack Oncology for $300M cash at close plus up to $150M milestones; MRD liquid biopsy tech.","Deal expected to close Q2 2023; modest dilution for 3 years, accretive by 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311237,"accession_number":"0000947871-23-000333","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quest Diagnostics updates 2023-2026 outlook: mid single-digit revenue CAGR, high single-digit adjusted EPS CAGR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.","Long-term 2023-2026: mid single-digit revenue CAGR; high single-digit adjusted EPS CAGR.","Invigorate program targets ~3% annual productivity savings via automation, AI, and digital.","Growth initiatives: physician/hospital expansion, molecular genomics, oncology, consumer health.","No change to 2023 guidance; capital deployment strategy discussed without new commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311236,"accession_number":"0001022079-23-000056","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Quest CEO James Davis elected Chairman of Board effective April 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James E. Davis, CEO and President, elected Chairman effective April 1, 2023.","Davis succeeds Stephen H. Rusckowski, who has been Chairman since Jan 2017.","Board combined roles stating it is in best interest of shareholders; Lead Independent Director Tim Ring remains.","Rusckowski remains Chairman through March 31, 2023; Davis became CEO on Nov 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311235,"accession_number":"0001022079-23-000006","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 revenue down 15% to $2.33B; base business up 6.3%; raises dividend 7.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported net revenues $2.33B (-15% YoY); base business revs $2.15B (+6.3%); COVID revs $184M (-74.6%).","Q4 reported diluted EPS $0.87 (down 72.1%); adjusted diluted EPS $1.98 (down 40.5%).","Full year 2022 net revenues $9.88B (-8.4%); base business revs $8.43B (+5.1%); COVID revs $1.45B (-47.5%).","FY2023 guidance: net revs $8.83-9.03B; base business up 2.6-3.8%; adjusted EPS $8.40-$9.00.","Board increased quarterly dividend 7.6% to $0.71 (payable Apr 24) and authorized additional $1B share repurchase."],"consensus_eps_estimate":null,"consensus_eps_actual":7.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":9883000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329849,"accession_number":"0001022079-22-000157","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Quest Diagnostics appoints four executive officers to severance plan; amends by-laws","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Four executives appointed as executive officers and Schedule B participants in severance plan: Mark Delaney, Mark Gardner, Karthik Kuppusamy, Patrick Plewman (effective Nov 16, 2022).","Board amended by-laws on Nov 14, 2022 regarding director nominations, proxy solicitations, and compliance with Rule 14a-19.","Schedule B participants receive 1x salary + 1x bonus pre-CIC; 2x salary + bonus post-CIC, plus benefits.","By-law amendments are ministerial, clarifying, and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329848,"accession_number":"0001022079-22-000150","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jim Davis becomes CEO and President of Quest Diagnostics; Rusckowski remains Chairman through March 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James E. Davis succeeds Steve Rusckowski as CEO and President effective November 1, 2022.","Board expanded from 9 to 10 directors; Davis elected to fill the vacancy.","Rusckowski, CEO since 2012, stays as Chairman until March 2023.","Transition was first announced on February 3, 2022.","Davis previously led Quest's COVID-19 operational response and held senior roles at GE and InSightec."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329847,"accession_number":"0001022079-22-000146","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics increases CEO Davis's salary to $1.1M, grants $5M equity upon promotion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Davis base salary raised to $1.1M, target annual incentive 150% of salary, effective Nov 1, 2022.","Equity grant of $5M: 60% performance shares (vest Feb 2025) and 40% RSUs (3-year cliff vest).","Transportation benefit up to $175k/yr; relocation benefits $125k flexible plus $25k legal/tax.","Davis moved to Schedule A of severance plan; share ownership guideline increased to 6x salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329846,"accession_number":"0001022079-22-000136","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics reports Q3 EPS $2.17, adjusted $2.36; raises 2022 guidance on base business growth of 5.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net revenues $2.49B, down 10.4% YoY; base business revenues $2.17B, up 5.1% YoY; COVID-19 testing $316M, down 55.4%.","Reported diluted EPS $2.17 (down 46.0%); adjusted diluted EPS $2.36 (down 40.4%).","Full-year 2022 guidance raised: net revenues $9.72B-$9.86B; adjusted EPS $9.75-$9.95 (prior $9.55-$9.95).","CEO transition: Jim Davis becomes CEO and President on Nov 1; Steve Rusckowski becomes Executive Chairman through March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":7.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":7550000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347429,"accession_number":"0001022079-22-000118","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).","Base business revenue $2.10B (+2.9% YoY); COVID testing revenue $355M (-30.5% YoY).","Raises FY22 guidance: net revenues $9.50B-$9.75B, adjusted EPS $9.55-$9.95 (prior $9.00-$9.50).","CEO-elect Jim Davis cites base business growth and expanded COVID molecular testing share.","Company supports SALSA legislation to fix PAMA clinical lab fee schedule cuts."],"consensus_eps_estimate":null,"consensus_eps_actual":4.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":5064000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347428,"accession_number":"0000947871-22-000737","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K/A","filed_at":"2022-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics details retirement terms for CEO Rusckowski; he'll serve as Executive Chairman through March 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen H. Rusckowski retires as CEO/President effective Nov 1, 2022; James E. Davis becomes CEO.","Rusckowski to serve as Executive Chairman until March 31, 2023; employment agreement not renewed.","Notice of non-renewal given June 29, 2022; compensation as Executive Chairman aligned with 2022 level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363882,"accession_number":"0001022079-22-000107","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quest Diagnostics names Sam Samad as EVP & CFO, effective July 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samad joins from Illumina (CFO since 2017); start date July 11, CFO role effective July 25.","Base salary $650k; target annual incentive 90% of base; initial equity grant $2.5M (50% performance shares, 25% options, 25% RSUs).","Sign-on inducement: cash payment of $1.2M (refundable if voluntary exit within 2 years) and RSUs valued at $1.5M vesting over 2 years.","Outgoing CFO Mark Guinan remains through Q2 earnings report for transition.","Samad eligible for executive severance plan, relocation benefits up to $105k, and share ownership guideline of 4x base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363881,"accession_number":"0001022079-22-000100","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics SVP Carrie Eglinton Manner resigns effective June 3, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie Eglinton Manner resigns as SVP, Advanced and General Diagnostics and Clinical Solutions.","Resignation effective June 3, 2022 to join OraSure Technologies, Inc.","No replacement announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363880,"accession_number":"0001022079-22-000079","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quest Diagnostics shareholders elect all 10 director nominees, approve say-on-pay, and pass charter amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with majority support; highest vote count 93.2M for Wright Lassiter III.","Advisory vote on executive compensation approved with 82.9M for, 10.3M against.","Ratification of PwC as auditor for 2022 approved with 96.9M for, 6.6M against.","Charter amendment allowing non-unanimous written consent passed with 91.1M for, 2.4M against.","Stockholder proposal on special meetings right failed with 39.1M for, 54.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363879,"accession_number":"0000947871-22-000627","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Quest Diagnostics amends charter to allow written consent, lower special meeting threshold to 15%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved written consent actions with minimum votes needed, replacing prior unanimous consent requirement.","Ownership threshold to request special meeting reduced from 20% to 15% of outstanding shares.","Amendment to Restated Certificate of Incorporation filed effective May 19, 2022.","Board amended and restated By-Laws to align with new consent and meeting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363878,"accession_number":"0001022079-22-000071","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics raises FY2022 guidance after Q1 base business grows 6.3%; adjusted EPS $3.22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenues $2.61B (-4.0% YoY); base business revenues $2.01B (+6.3% YoY); COVID revenues $599M (-27.6%).","Reported diluted EPS $2.92 (-15.6%); adjusted diluted EPS $3.22 (-14.4%).","Full year 2022 guidance raised: reported EPS $7.88-$8.38; adjusted EPS $9.00-$9.50; revenues $9.2B-$9.5B.","Cash from operations $480M (-34.2%); capex $63M (-26.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2611000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383623,"accession_number":"0001022079-22-000048","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics director Dr. Helen I. Torley will not seek re-election; board size reduced to 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Torley, President & CEO of Halozyme, chose not to stand for re-election at the May 18, 2022 annual meeting.","Board reduced its size from 10 to 9 directors, effective at the annual meeting.","Dr. Torley cited a desire to focus on board service for companies developing innovative medicines.","No disagreement with the company was disclosed regarding her departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383622,"accession_number":"0001022079-22-000046","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics CFO Mark Guinan to retire in 2022; special equity grant to senior VP for succession","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mark Guinan received annual equity grant of $1.12M, half of 2021 grant, with accelerated vesting upon retirement.","Carrie Eglinton Manner received special grant of $1.94M (50% performance shares, 50% RSUs) to promote succession and revenue growth.","Performance shares vest based on CAGR of revenue in Diagnostic Information Services, excluding COVID-19 and post-January 2022 acquisitions.","Both grants cliff vest on third anniversary; no accelerated vesting for qualifying retirement for Manner's grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383618,"accession_number":"0001022079-22-000045","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K/A","filed_at":"2022-03-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics details CEO-Elect James Davis's 2022 compensation: $800K salary, $4.88M LTI","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $800,000, target annual bonus 100% of salary, LTI award $4,880,649.","LTI award consists of 50% performance shares (3-yr), 25% stock options, 25% RSUs.","Performance share metrics: base revenue CAGR (35%), COVID-19 revenues (15%), ROIC (30%), relative TSR (20%).","Terms substantially similar to those of other Quest executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383621,"accession_number":"0001022079-22-000008","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 revenue down 8.6%, FY record $10.8B; raises dividend 6.5%; FY2022 guide adj EPS $8.65-$9.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fourth quarter revenues $2.74B (-8.6% YoY); diluted EPS $3.12 reported, $3.33 adjusted (-25.7% adj.).","Full year 2021 revenues $10.79B (+14.3%); diluted EPS $15.55 reported, $14.24 adjusted (+27.4% adj.).","Board increased quarterly dividend 6.5% to $0.66/share, payable April 20, 2022, record April 6, 2022.","FY2022 guidance: revenues $9.0-$9.5B, adj. diluted EPS $8.65-$9.35; base business revenue growth 3.5%-6.0%.","Cash from operations FY2021 $2.23B (+11.4% YoY); FY2022 cash from operations guided at least $1.6B."],"consensus_eps_estimate":null,"consensus_eps_actual":15.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":10788000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383620,"accession_number":"0000947871-22-000132","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quest Diagnostics appoints James E. Davis as CEO-elect; CFO Mark Guinan to retire in 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James E. Davis appointed CEO-elect effective Feb. 3, 2022; to become CEO and President on Nov. 1, 2022.","Current CEO Steve Rusckowski to remain CEO through Oct. 2022 then serve as Executive Chairman through Mar. 2023.","CFO Mark Guinan announces retirement in 2022; company begins search for successor.","Davis currently EVP of General Diagnostics, overseeing >80% of $10.8B 2021 revenue.","Transition reflects planned succession; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383619,"accession_number":"0001022079-22-000005","cik":1022079,"company_name":"QUEST DIAGNOSTICS INC","ticker":"DGX","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quest Diagnostics Q4 rev $2.74B (-9% YoY); FY EPS beats outlook; 2022 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 revenue ~$2.74B, down 9% from $3.00B in Q4 2020.","Q4 reported diluted EPS $3.12; adjusted diluted EPS $3.33 (vs $4.48 adjusted in Q4 2020).","Full year 2021 revenue ~$10.79B (+14% YoY); adjusted diluted EPS $14.24 exceeded prior outlook.","COVID-19 testing demand higher than expected; Q4 included 7.9M molecular tests and 0.7M serology tests.","2022 guidance raised: now expects adjusted diluted EPS above $8.00 (prior was near upper end of $7.40-$8.00)."],"consensus_eps_estimate":null,"consensus_eps_actual":15.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":10788000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21474000299.405693,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-12T23:59:59+00:00|383619"}